Emoxipin(Emoxipin) - 在研适应症：缺血性卒中，缺血性脑损伤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Mexidol

靶点-

作用方式-

作用机制-

治疗领域

神经系统疾病心血管疾病

在研适应症

缺血性卒中缺血性脑损伤

非在研适应症

焦虑症脑梗塞认知障碍+ [3]

原研机构

Russian Academy of Sciences

在研机构

Pharmasoft Ilaç Bilisim Danismanlik Hizmetleri Ltd. Sti

非在研机构

Russian Academy of Sciences

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C8H11NO

InChIKeyJPGDYIGSCHWQCC-UHFFFAOYSA-N

CAS号2364-75-2

查看全部结构式(2)

关联

7

项与 Emoxipin 相关的临床试验

NCT06437639

/ Completed临床4期

Prospective, Open, Comparative, Randomized Study of the Efficacy and Safety Evaluation of the Mexidol® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.

开始日期2023-09-15

申办/合作机构

Pharmasoft Ilaç Bilisim Danismanlik Hizmetleri Ltd. Sti

NCT06221826

/ Completed临床4期

Prospective Randomized Study of the Modulating Effect of MEXIDOL® as an Adjuvant Stimulant of the Cognitive-emotional Component of the Rehabilitation Treatment in Patients With Acute Cerebral Failure

The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure

开始日期2023-04-17

申办/合作机构

Pharmasoft Ilaç Bilisim Danismanlik Hizmetleri Ltd. Sti

NCT06903156

/ Completed临床2期

Prospective Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel-group Comparative Trial of the Efficacy and Safety of Different Dosages in Sequential Therapy With Mexidol® in Patients With Primary Open-angle Glaucoma

The present trial is planned to investigate and identify the best dosage of investigational drugs with respect to the treatment of open-angle glaucoma. Therefore, multiple dose regimens of the investigational drug versus placebo drug are anticipated.

开始日期2021-11-15

申办/合作机构

Pharmasoft Ilaç Bilisim Danismanlik Hizmetleri Ltd. Sti

100 项与 Emoxipin 相关的临床结果

登录后查看更多信息

100 项与 Emoxipin 相关的转化医学

登录后查看更多信息

100 项与 Emoxipin 相关的专利（医药）

登录后查看更多信息

865

项与 Emoxipin 相关的文献（医药）

2025-05-01·Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

Cost effectiveness analysis of expanding tuberculosis preventive therapy to household contacts aged 5–14 years in the Philippines

Article

作者: Bassiag, Flordeliza R ; Thomas, Tania A ; Keim-Malpass, Jessica ; Ilaiwy, Ghassan ; Tuppal, Romella ; Ritua, Alexander F

BackgroundChildren aged 5-14 years who are household contacts (HHCs) of index people with active TB disease (PWTB) have limited coverage for TB preventive therapy (TPT) due to variable uptake of the national guideline recommendations in the Philippines. We conducted a cost-effectiveness analysis evaluating the expansion of TB infection (TBI) testing and treatment among pediatric (5-14 years) HHCs of index PWTB in the Philippines to assist the National TB program in choosing the most cost-effective testing and treatment strategy for TBI among HHCs of index PWTB.MethodsUsing a Markov state transition model, eligible HHCs age 5-14 years are screened for TBI with either the tuberculin skin test (TST) or interferon gamma release assay (IGRA). Those who test positive are then simulated to receive one of the following TPT strategies: 6 months of daily isoniazid (6H), 3 months of weekly isoniazid and rifapentine (3HP), 3 months of daily isoniazid plus rifampicin (3HR) and the current practice of no testing or treatment for TBI (NTT). The analysis assesses the projected cost and quality-adjusted life years (QALY) gained for every strategy from the perspective of the Philippines public healthcare system over a time horizon of 20 years. The total cost and gain in QALYs are presented as an incremental cost-effectiveness ratio (ICER) comparing cost per QALY gained for each strategy over NTT.ResultsOur model estimates that expanding TPT coverage to HHCs aged 5-14 years would be cost-effective with incremental cost-effectiveness ratios (ICERs) ranging from 1,024 $/QALY gained when using TST and 6H (Uncertainty range: 497---2,334) to 2,293 $/QALY gained when IGRA and 3HR are used (Uncertainty range: 1,140 - 5,203). These findings were robust to sensitivity analyses over a wide range of parameter values.ConclusionExpanding TPT coverage to HHCs aged 5-14 years is cost-effective when using TST and 6H closely followed by a strategy combining TST and 3HP.

2025-04-08·S.S. Korsakov Journal of Neurology and Psychiatry

Personal characteristics of patients with cerebral microangiopathy

Article

作者: Antoshina, A.B. ; Slyusar, T.A. ; Slyusar, I.N. ; Abramova, V.N. ; Abramenko, Yu.V.

Objective. To study the personality characteristics of patients with cerebral microangiopathy (CMA) and evaluate the effect of sequential therapy with Mexidol (500 mg injections intravenously for 14 days) and Mexidol FORTE 250 (250 mg tablets 3 times a day for 60 days) on the personal characteristics of patients with CMA. Material and methods. 130 patients aged 55—70 years (72 women and 58 men) with CMA, who received Mexidol as part of the complex treatment according to the specified scheme. The neuropsychological study included the study of personality traits using the multifactorial personality questionnaire of R. Cattell and the Freiburg personality questionnaire, MRI. The neuropsychological examination included the study of personality characteristics using the R. Cattell multifactorial personality research questionnaire (form C) and the Freiburg Personality Questionnaire (variant B). Results. Patients with CMA were characterized by heterogeneity of personality characteristics, the severity and diversity of which changed as the disease progressed. The course of treatment with Mexidol led to a decrease in the representation and severity of personality changes. Conclusion. The high efficacy and safety of long-term sequential therapy with Mexidol and Mexidol FORTE 250 has been demonstrated.

2025-03-06·S.S. Korsakov Journal of Neurology and Psychiatry

The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment

Article

作者: Yakusheva, E.N. ; Kruzhalov, N.A. ; Abalenikhina, Yu.V. ; Shchulkin, A.V. ; Chernykh, I.V. ; Andryushina, O.A. ; Gatsanoga, M.V.

Objective. To study the effect of Mexidol on the level of factors regulating neuroregenesis. Material and methods. The study was performed on male Wistar rats. Focal cerebral ischemia was reproduced by endovascular occlusion-reperfusion of the right medial cerebral artery. The duration of occlusion was 60 min. During the beginning of reperfusion, the animals were given a single intravenous injection of saline solution or the drug Mexidol at a dose of 50 mg/kg. 4, 8 and 24 hours after the beginning of reperfusion in the ischemic hemisphere, the relative amount of molecules regulating neurogenesis was estimated by Western blot method. Additionally, 24 hours after the start of reperfusion, the size of the brain infarction was analyzed after staining with a 1% solution of 2.3,5,-triphenyltetrazolium. Results. When modeling occlusion-reperfusion of the middle cerebral artery, the volume of necrosis in the affected hemisphere of animals injected with saline was 37.75±7.46%, administration of Mexidol at a dose of 50 mg /kg led to a decrease in the volume of necrosis to 20.48±2.33% (p=0.0006). The simulation of occlusion-reperfusion of the middle cerebral artery was accompanied by activation of neurotrophic factors IGF-1, NGF and vascular factor VEGF. A single intravenous administration of Mexidol at a dose of 50 mg/kg during reperfusion increased the level of neurotrophic factors IGF-1, NGF, BDNF and VEGF in the ischemic area of the brain compared with the administration of saline, which leads to increased neuroregeneration at all follow-up periods (4, 8 and 24 hours after reperfusion), the marker of which is tubulin-3. Conclusion. The results suggest that Mexidol not only has a protective effect on neurons, but can also stimulate neuroregeneration by increasing the level of the main regulatory molecules.

100 项与 Emoxipin 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
缺血性卒中	临床3期	俄罗斯	Pharmasoft Ilaç Bilisim Danismanlik Hizmetleri Ltd. Sti	2015-03-06
缺血性脑损伤	临床前	-	-	2020-02-01
脑梗塞	药物发现	俄罗斯	Pharmasoft Ilaç Bilisim Danismanlik Hizmetleri Ltd. Sti	2019-11-05
脑梗塞	药物发现	乌兹别克斯坦	Pharmasoft Ilaç Bilisim Danismanlik Hizmetleri Ltd. Sti	2019-11-05
焦虑症	药物发现	-	Russian Academy of Sciences	-
认知障碍	药物发现	-	Russian Academy of Sciences	-
心肌缺血	药物发现	-	Russian Academy of Sciences	-
胰腺炎	药物发现	-	Russian Academy of Sciences	-
消化性溃疡	药物发现	-	Russian Academy of Sciences	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02793687 (EPICA, CTgov)	临床3期	缺血性卒中	150	Mexidol (Mexidol®)	(壓積鏇餘觸鬱齋遞願繭) = 糧網構繭夢憲範鑰蓋餘簾鬱憲願選選繭顧遞糧 (窪蓋築鹹觸築夢鹹憲蓋, 壓壓積憲製繭齋齋簾鬱 ~ 鹹繭醖膚願膚鏇繭蓋簾) 更多	-	2025-02-24
				Placebo (Placebo)	(壓積鏇餘觸鬱齋遞願繭) = 醖淵鬱憲鏇製遞繭簾構簾鬱憲願選選繭顧遞糧 (窪蓋築鹹觸築夢鹹憲蓋, 蓋餘鹽襯淵鹽遞壓膚淵 ~ 膚餘艱蓋襯餘廠範糧繭) 更多